OvC (second/third line) a. Histologically diagnosed ovarian, fallopian tu be or primary peritoneal cancer at the time of initial presentation. b. Patients will have either relapsed or be disease resistant to their prior therapy. Interval surgery is permitted, but patients must have objective evidence of disease on computed tomography (CT) or magnetic resonance imaging ( MRI), with concomitant CA-125 increase and/or biopsy showing OvC (only for recurrent disease). c. Patients should have received platinum-containing chemotherapy and been designated as harboring platinum-refractory or -resistant disease. Additionally, all eligible subjects should have either received (or been offered) bevacizumab therapy, and those with BRCA germline mutations (gBRCA mut) should have been offered therapy with poly-ADP ribose polymerase (PARP) inhibitors (olaparib, rucaparib or niraparib). (iii).